Fosamprenavir expanded access in UK
1 April 2003. Related: Antiretrovirals, Other news.
Antiretrovirals
Roche prices enfuvirtide (T-20) at €18,980 a year – making it the most expensive HIV drug yet
1 April 2003. Related: Antiretrovirals.
European positive opinion for tenofovir for first-line therapy
1 April 2003. Related: Antiretrovirals.
Efficacy and safety of a quadruple combination Combivir + abacavir + efavirenz regimen in antiretroviral treatment-naive HIV-1-infected adults: La Francilienne
1 March 2003. Related: Antiretrovirals.
Combination of three generic drugs in one pill meets bioequivalence criteria when compared with the branded drugs: Triomune vs d4T/3TC/NVP
1 February 2003. Related: Conference reports, Antiretrovirals, Treatment access.
An overview of the conference
1 February 2003. Related: Conference reports, Antiretrovirals, Weight, diabetes, metabolic complications.
Pharmacokinetic evaluation of tenofovir and enteric-coated ddI
1 February 2003. Related: Conference reports, Antiretrovirals, PK and drug interactions.
The advantages of fosamprenavir; comparing saquinavir/r to lopinavir/r; reducing viral load to <3 copies; AZT-d4T cross resistance; and rising HCV rates
1 February 2003. Related: Conference reports, Antiretrovirals, Treatment strategies, Hepatitis coinfection, Drug resistance.
Enfuvirtide (T-20): predicting success and modelling survival benefits
1 February 2003. Related: Conference reports, Antiretrovirals, Drug resistance.
Virologic failure among treatment-naive patients taking tenofovir DF or stavudine in combination with lamivudine and efavirenz
1 February 2003. Related: Conference reports, Antiretrovirals.
Comparison of the efficacy and safety of tenofovir vs. d4T when used in combination with 3TC and efavirenz in ARV-naive patients
1 February 2003. Related: Conference reports, Antiretrovirals, Side effects, Weight, diabetes, metabolic complications.
Safety profile of tenofovir in treatment-experienced patients
1 February 2003. Related: Conference reports, Antiretrovirals, Side effects.
Roche and Trimeris able to make enough enfuvirtide (T-20) for only 12,000 people this year, 32,000 next year, citing difficulties in the manufacturing process
1 February 2003. Related: Antiretrovirals.
Vertex Pharmaceuticals announces submission of NDA/MAA filings in US and Europe for amprenavir pro-drug (GW433908)
1 February 2003. Related: Antiretrovirals.
BMS submits new drug application for investigational protease inhibitior atazanavir
1 February 2003. Related: Antiretrovirals.
Europe and America approve once-a-day stavudine (d4T, Zerit)
1 February 2003. Related: Antiretrovirals.
Tenofovir as HIV prevention: study to reduce HIV transmission in sexually active adults
1 February 2003. Related: Antiretrovirals.
Boehringer chooses dose for phase III studies of tipranavir/ritonavir PI combination
1 February 2003. Related: Antiretrovirals.
Boosted PIs: differences emerging in efficacy, tolerability, lipids
1 December 2002. Related: Antiretrovirals.
Europe steps in to protect discounted drugs for developing countries
1 December 2002. Related: Antiretrovirals.
Hair analysis may help determine drug levels, adherence and virological response
1 December 2002. Related: Antiretrovirals.
Disadvantage from prior nucleoside therapy persists for years during HAART
1 December 2002. Related: Antiretrovirals.
BMS experimental PI atazanavir shows potency comparable to NNRTI efavirenz among treatment-naïve HIV patients
13 November 2002. Related: Conference reports, Antiretrovirals.
New evidence favours routine measurement of plasma concentrations in salvage therapy to maintain sustained drug levels
13 November 2002. Related: Antiretrovirals.
New safety information for ddI used with ribavirin
13 November 2002. Related: Treatment alerts, Antiretrovirals.
US FDA issues new safety information for tenofovir co-administration with ddI
13 November 2002. Related: Treatment alerts, Antiretrovirals.
European Commission approves new boosted saquinavir regimen (1000 mg saquinavir/100 mg ritonavir twice daily) for the treatment of HIV-1
13 November 2002. Related: Antiretrovirals.
US HIV community hold productive meeting with Schering-Plough on new anti-HIV entry inhibitors SCH-C and SCH-D
13 October 2002. Related: Antiretrovirals.
Notes on Schering-Plough/HIV community meeting held August 28 2002
13 October 2002. Related: Antiretrovirals.
US FDA announces important changes in amprenavir product labelling
13 October 2002. Related: Antiretrovirals, PK and drug interactions.
Much lower dose of lamivudine needed for HIV-positive patients on dialysis
13 October 2002. Related: Antiretrovirals.
Patients discontinuing HAART must be carefully monitored
13 October 2002. Related: Antiretrovirals.
New anti-HIV compounds discussed at the Seville HIV Drug Resistance Workshop and the Barcelona World AIDS Conference
11 September 2002. Related: Conference reports, Antiretrovirals.
Management of people with treatment experience and drug resistance
11 September 2002. Related: Conference reports, Antiretrovirals.
Lopinavir/r exhibits sustained virologic response in antiretroviral-naïve patients: 3-year data
11 September 2002. Related: Conference reports, Antiretrovirals.
Patients will have options regarding T-20 (enfuvirtide) injection sites
11 September 2002. Related: Conference reports, Antiretrovirals.
The role of tenofovir in antiretroviral-naive patients
11 September 2002. Related: Conference reports, Antiretrovirals.
New data from clinical trials of antiretrovirals
11 September 2002. Related: Conference reports, Antiretrovirals.
Trial supports lopinavir/ritonavir as first-line therapy in HIV infection
11 September 2002. Related: Antiretrovirals.
Ritonavir has anti-neoplastic effects independent of HIV inhibition
11 September 2002. Related: Antiretrovirals.
Pharmacokinetics and further benefits of therapeutic drug monitoring (TDM)
11 September 2002. Related: Antiretrovirals.
BMS advice on interaction between didanosine EC and tenofovir
11 July 2002. Related: Treatment alerts, Antiretrovirals.
Optimal antiretroviral drug levels improve outcomes
11 July 2002. Related: Antiretrovirals.
Roche and Trimeris announce 24-week results from second pivotal study of HIV fusion inhibitor T-20
11 July 2002. Related: Antiretrovirals.
New study adds to evidence showing adherence is linked to survival
11 July 2002. Related: Antiretrovirals.
Intermittent use of ART is associated with increased mortality
11 July 2002. Related: Antiretrovirals.
Amprenavir mutations may significantly affect LPV resistance
11 June 2002. Related: Antiretrovirals, Drug resistance.
24-week results from phase III study of HIV fusion inhibitor T-20
11 June 2002. Related: Antiretrovirals.
Abacavir treatment limited by prior NRTI exposure
11 June 2002. Related: Antiretrovirals, Drug resistance.
Hydroxyurea: in vitro evidence of potency against HIV viral reservoirs
11 May 2002. Related: Antiretrovirals.
Transient increases in viral load are common among people on HAART, finds a study of UK patients
11 May 2002. Related: Antiretrovirals.
Meta-analysis supports triple therapy for HIV infection
11 May 2002. Related: Antiretrovirals.
New drugs: perhaps some genuine excitement this time
10 April 2002. Related: Conference reports, Antiretrovirals.
T20 and beyond: inhibition of HIV attachment and fusion at the 9th CROI
10 April 2002. Related: Conference reports, Antiretrovirals.
Pharmacogenetics predict abacavir hypersensitivity
10 April 2002. Related: Conference reports, Antiretrovirals.
Hepatic injury with nevirapine related to drug level and hepatitis C infection
10 March 2002. Related: Antiretrovirals, Side effects.
Study finds that PI-containing regimens have a beneficial effect on oral candidiasis independent of any immune reconstitution
10 March 2002. Related: Antiretrovirals, Coinfections and complications.
Tenofovir DF approved for marketing in European Union
10 March 2002. Related: Antiretrovirals.
It may be important to screen and treat riboflavin deficiency in patients on nucleoside analogues
10 March 2002. Related: Antiretrovirals, Side effects.
Factors associated with immunologic stability despite protease inhibitor based HAART “failure”
10 March 2002. Related: Antiretrovirals.
NIAID funds 9-year, 6,000-participant study to look at how best to use antiretrovirals
10 March 2002. Related: Antiretrovirals.
Impaired response to HAART found in HIV-positive individuals with high autonomic nervous system activity
10 January 2002. Related: Antiretrovirals.
Anti-HIV effects of the malarial drug chloroquine
10 January 2002. Related: Antiretrovirals.
Treatment guidelines should place more emphasis on CD4+ counts than on viral loads
10 January 2002. Related: Antiretrovirals.
Impact of Kaletra on amprenavir plasma concentrations in HIV treatment-experienced patients
9 January 2002. Related: Conference reports, Antiretrovirals.